Advertisement

Current developments in cancer care: including the patients’ perspective—3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany

  • O. OrtmannEmail author
  • W. Rösler
  • U. Helbig
  • for the participants of the ERTM
Review – Clinical Oncology

Abstract

Purpose

National Cancer Control Plans (NCCP) are necessary to improve cancer care and reduce mortality. We have reported previously on European institutional health structures and transformation of theoretical health care standards into a practical approach. For the latter consideration of the patients’ perspective was considered as highly important and chosen as subject for this meeting.

Results

Several European organizations have realized deficits in this area. They promote equal and timely access to cancer care since current inequities lead to disparities in cancer survival across Europe. Patients’ support working groups are focussing on employment issues, financial services, psychosocial screening and support, palliative care and rehabilitation. They also identified cancer research including patients’ views as highly important. Workshops during the 3rd European Roundtable Meeting (ERTM) covered the issues transparency in patient care, implementation of new knowledge and decision making in partnership with the patient.

Conclusions

It was concluded that patient views and perspectives have to be considered during the whole continuum of cancer care. Access to treatment, transparency and including patients into the development process are relevant aspects.

Keywords

National Cancer Control Plan Cancer care Patient perspective Shared decision making Transparency Access to cancer care Cancer research 

Notes

Author contribution

OO, WR and UH have contributed to manuscript writing, editing.

List of ERTM participants

Prof. Dr. Josep M. Borras, (Director, Catalan Cancer Plan, Spain); Anke Bramesfeld, (Scientific/Technical Project Officer, DG Joint Research Centre, Institute for Health Policy Support Unit, Healthcare Quality Team, Italy); Dr. Johannes Bruns, (Secretary-General, German Cancer Society (DKG), Germany); Prof. Dr. Jan-Willem Coebergh, (form. Director, Department of Public Health Erasmus Institute, Netherlands); Prof. Dr. Francesco de Lorenzo, (President of the European Cancer Patient Coalition, Belgium/European Union); David H.-U. Haerry, (European Aids Treatment Group, Belgium/European Union); Prof. Dr. Michael Hallek, (Director and Chair of the Department of Internal Medicine at the University of Cologne, Germany); Dr. Ulrike Helbig, (General Manager of the Section A, International Coordination, German Cancer Society, Germany); Joan Kelly, (Past President of the Association of European Cancer Leagues, Belgium/European Union); PD Dr. Monika Klinkhammer-Schalke, (Managing Board Member, ADT, Germany); Dr. Christoph Kowalski, (Research Coordination Certification, German Cancer Society (DKG), Germany); Prof. Dr. Margarete Landenberger (a.D., Institute of Health and Nursing Science, Medical Faculty of Martin-Luther University Halle-Wittenberg, Germany); Dr. Katrin Mugele, (Press Officer, German Cancer Society (DKG), Germany); Dr. Alice Nennecke, (Cancer Registry Hamburg, Institute of Health and Consumer Protection Hamburg, Germany); Prof. Dr. Olaf Ortmann, (Vice-President, German Cancer Society (DKG), Germany); Prof. Dr. Ulrik Ringborg, (Director Cancer Center Karolinska, Sweden); Dr. Wiebke Rösler, (Global Resources Manager, Union for International Cancer Control (UICC), Switzerland/Global); Hilde Schulte, (Former President, Frauenselbsthilfe nach Krebs, Haus der Krebs-Selbsthilfe-Bundesverband, Germany); Dr. Wendy Yared, (Director of the Association of European Cancer Leagues, Brussels/European Union).

Compliance with ethical standards

Conflict of interest

Authors U. Helbig M.D., W. Rösler and O. Ortmann M.D. declare that they have no conflict of interest.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. Ades F, Senterre C, Zardavas D et al (2014) An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case. Eur J Cancer 50(18):3089–3097CrossRefPubMedGoogle Scholar
  2. Association of European Cancer Leagues. www.europeancancerleagues.org
  3. Cancer Control Joint Action. www.cancercontrol.eu/
  4. De Angelis R, Sant M, Coleman MP et al (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE 5—a population-based study. Lancet Oncol 15(1):23–34CrossRefPubMedGoogle Scholar
  5. European Cancer Patient Coalition. www.ecpc.org
  6. Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12):1165–1174CrossRefPubMedGoogle Scholar
  7. Martin Moreno JM, Albrecht T, Rados Kruel S et al. (2013) Boosting Innovation and cooperation in European Cancer Control: key findings from the European Partnership for Action Against Cancer (EPAAC) National Institution of Public Health of the Republic of Slovenia and World Health Organization. www.epaac.eu/
  8. Ortmann O, Helbig K, Torode J (2015a) Improving cancer care in Europe: which institutional health structures might be beneficial and why? 1. European Roundtable Meeting (ERTM), 16th May 2014, Berlin, Germany. J Cancer Res Clin Oncol. doi: 10.1007/s00432-014-1906-x PubMedCentralGoogle Scholar
  9. Ortmann O, Torode J, Helbig U (2015b) Improving structural development in oncology: transformation of theoretical health care standards and knowledge into a practical approach—2nd European Roundtable Meeting (ERTM), May 8, 2015, Berlin, Germany. J Cancer Res Clin Oncol. doi: 10.1007/s00432-015-2052-9 PubMedCentralGoogle Scholar
  10. van de Poll-Franse LV, Horevoorts N, van Eenbergen M et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • O. Ortmann
    • 1
    • 3
    Email author
  • W. Rösler
    • 2
  • U. Helbig
    • 1
  • for the participants of the ERTM
  1. 1.German Cancer SocietyBerlinGermany
  2. 2.Union for International Cancer Control (UICC)GenevaSwitzerland
  3. 3.Department of Gynecology and ObstetricsUniversity Medical Center RegensburgRegensburgGermany

Personalised recommendations